MedDataX Logo

To Evaluate Long-Term Safety and Efficacy of Pregabalin in the Treatment of Neuropathic Pain After Spinal Cord Injury.

NCT ID: NCT00141375

Last Updated: 2008-01-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

132 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-08-31

Study Completion Date

2006-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate long-term safety and efficacy of pregabalin in the treatment of neuropathic pain after spinal cord injury.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design

NCT00978341

Spinal Cord Injuries
TERMINATED NA

An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain

NCT01202227

Spinal Cord Diseases Spinal Cord Injuries Neuralgia +1 more
COMPLETED PHASE3

Study of Pregabalin in the Prevention of Central Neuropathic Pain in Acute Spinal Cord Injury

NCT00879021

Spinal Cord Trauma Pain
TERMINATED PHASE3

A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

NCT00407745

Neuralgia Spinal Cord Injuries
COMPLETED PHASE3

Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Chronic Neuropathic Pain.

NCT00141362

Pain
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuropathic Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pregabalin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have received study medication under double-blind conditions.

Exclusion Criteria

* Patients cannot participate if they experienced a serious adverse event during the previous double-blind BID study which was determined to be related to the study medication.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

Little Bay, New South Wales, Australia

Site Status

Pfizer Investigational Site

St Leonards, New South Wales, Australia

Site Status

Pfizer Investigational Site

Warrawong, New South Wales, Australia

Site Status

Pfizer Investigational Site

Woolloongabba, Queensland, Australia

Site Status

Pfizer Investigational Site

Heidelberg, Victoria, Australia

Site Status

Pfizer Investigational Site

Shenton Park, Western Australia, Australia

Site Status

Pfizer Investigational Site

NSW, , Australia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Australia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1008-000-202

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prophylactic Pregabalin Treatment Following Spinal Cord Injury
NCT06066918 RECRUITING NA
Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
NCT01603394 TERMINATED PHASE4
Efficacy Of Pregabalin In Subjects With Post-Stroke Central Neuropathic Pain
NCT00313820 COMPLETED PHASE4
A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia
NCT00424372 COMPLETED PHASE3
Open Label Safety And Efficacy Study Of Pregabalin In Subjects With Nerve Pain Asociated With Human Immunodeficiency Virus (HIV) Neuropathy
NCT00264875 COMPLETED PHASE3
Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain
NCT01479556 UNKNOWN PHASE4
Pregabalin add-on for Neuropathic Pain in Cervical Myelopathy
NCT03618589 UNKNOWN PHASE1
Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy.
NCT00141401 COMPLETED PHASE3
To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.
NCT00150423 COMPLETED PHASE3
Trial of Efficacy and Safety of Pregabalin in Subjects With Neuropathic Pain Associated With Lumbo-Sacral Radiculopathy
NCT00159705 COMPLETED PHASE3
Placebo-controlled Safety and Efficacy Study of Pregabalin in Subjects With Post-traumatic Peripheral Neuropathic Pain
NCT01701362 COMPLETED PHASE3
Efficacy Study Measuring the Impact of Pregabalin on Peripheral Neuropathic Pain.
NCT00219544 COMPLETED PHASE3
Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
NCT00143156 COMPLETED PHASE3
Pregabalin for Treatment of Patients With Postherpetic Neuralgia (PHN)
NCT01455428 COMPLETED PHASE4
Evaluation of Pregabalin in Idiopathic Small Fiber Neuropathy
NCT00787462 TERMINATED NA
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Postherpetic Neuralgia.
NCT00150436 COMPLETED PHASE3
Management of Pain Associated With Failed Back Surgery Syndrome
NCT05324761 COMPLETED PHASE4
Pregabalin Peripheral Neuropathic Pain Study
NCT00141219 COMPLETED PHASE3
This Study is An Open-Label Trial Of Pregabalin In Patients With Fibromyalgia
NCT00346034 COMPLETED PHASE3
Pharmacokinetics of Two Formulation of Pregabalin
NCT03712475 COMPLETED PHASE4
Efficacy of Perioperative Pregabalin in Reducing the Incidence of Chronic Neuropathic Pain and Postthoracotomy Syndrome.
NCT00967135 COMPLETED NA
Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy
NCT00553475 COMPLETED PHASE3
Pregabalin is an Effective Treatment for Acute Postoperative Pain Following Spinal Surgery Without Major Side Effects
NCT05478382 NOT_YET_RECRUITING PHASE4
Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement
NCT00729690 COMPLETED PHASE3
Effect Of Pregabalin Treatment In Patients With Diabetic Nerve Pain Who Currently Use A Non-Steroid Anti-Inflammatory Drug (NSAID) For Another Pain
NCT01455415 COMPLETED PHASE3